Refining α-synucleinopathy risk in isolated REM sleep behavior disorder patients using repeated olfactory testing
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F25%3A10504120" target="_blank" >RIV/00216208:11110/25:10504120 - isvavai.cz</a>
Alternative codes found
RIV/68407700:21230/25:00385807 RIV/00064165:_____/25:10504120
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ttGn-3gM6l" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ttGn-3gM6l</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.sleep.2025.106812" target="_blank" >10.1016/j.sleep.2025.106812</a>
Alternative languages
Result language
angličtina
Original language name
Refining α-synucleinopathy risk in isolated REM sleep behavior disorder patients using repeated olfactory testing
Original language description
Objective This study investigated the prognostic utility of repeated olfactory testing in patients with isolated REM sleep behavior disorder (iRBD) for predicting phenoconversion to overt alpha-synucleinopathies. Methods We analyzed 59 iRBD patients (mean age: 66.9 +/- 7.2 years; 91.5 % male) who underwent olfactory testing using the University of Pennsylvania Smell Identification Test at baseline and at a two-year follow-up. Patients were classified into persistent hyposmia, persistent normosmia, or unstable olfactory function groups. Clinical, cognitive, and dopamine transporter single photon emission CT (DAT-SPECT) parameters were assessed longitudinally. Results Olfactory function remained stable in most patients. The persistent hyposmia group (n = 37, 62.7 %) exhibited higher age, worse DAT-SPECT indices, and significant progression in MDS-UPDRS III over two years. In contrast, the persistent normosmia group (n = 11, 18.6 %) showed no significant neurodegenerative changes and had a 0 % phenoconversion rate over similar to 5 years. Phenoconversion occurred in 20.3 % of patients, predominantly among those with persistent hyposmia (9/12 converters) and in patients from the unstable olfactory group (3/12 converts). While baseline hyposmia alone did not predict phenoconversion, repeated hyposmia significantly increased the risk (p < 0.05). Conclusion Repeated olfactory testing improves risk stratification in iRBD. Persistent normosmia is associated with a lower risk of phenoconversion, whereas persistent hyposmia predicts neurodegeneration. Serial olfactory assessments may serve as a cost-effective tool for identifying high-risk patients and refining recruitment for neuroprotective trials.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Sleep Medicine
ISSN
1389-9457
e-ISSN
1878-5506
Volume of the periodical
136
Issue of the periodical within the volume
December
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
8
Pages from-to
106812
UT code for WoS article
001586982900003
EID of the result in the Scopus database
2-s2.0-105017074047